Literature DB >> 31675090

Talking the Talk About Tumor Genomic Testing.

Richard L Schilsky1.   

Abstract

Entities:  

Year:  2020        PMID： 31675090      PMCID： PMC7225677          DOI： 10.1093/jnci/djz175

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  16 in total

1.  Full disclosure--out-of-pocket costs as side effects.

Authors:  Peter A Ubel; Amy P Abernethy; S Yousuf Zafar
Journal:  N Engl J Med       Date:  2013-10-17       Impact factor: 91.245

2.  Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.

Authors:  Shi-Yi Wang; Weixiong Dang; Ilana Richman; Sarah S Mougalian; Suzanne B Evans; Cary P Gross
Journal:  J Clin Oncol       Date:  2018-04-16       Impact factor: 44.544

3.  American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.

Authors:  Lowell E Schnipper; Nancy E Davidson; Dana S Wollins; Courtney Tyne; Douglas W Blayney; Diane Blum; Adam P Dicker; Patricia A Ganz; J Russell Hoverman; Robert Langdon; Gary H Lyman; Neal J Meropol; Therese Mulvey; Lee Newcomer; Jeffrey Peppercorn; Blase Polite; Derek Raghavan; Gregory Rossi; Leonard Saltz; Deborah Schrag; Thomas J Smith; Peter P Yu; Clifford A Hudis; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2015-06-22       Impact factor: 44.544

4.  A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

Authors:  N I Cherny; R Sullivan; U Dafni; J M Kerst; A Sobrero; C Zielinski; E G E de Vries; M J Piccart
Journal:  Ann Oncol       Date:  2015-05-30       Impact factor: 32.976

5.  Molecular screening to select therapy for advanced cancer?

Authors:  I F Tannock; J A Hickman
Journal:  Ann Oncol       Date:  2019-05-01       Impact factor: 32.976

6.  Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.

Authors:  Lowell E Schnipper; Nancy E Davidson; Dana S Wollins; Douglas W Blayney; Adam P Dicker; Patricia A Ganz; J Russell Hoverman; Robert Langdon; Gary H Lyman; Neal J Meropol; Therese Mulvey; Lee Newcomer; Jeffrey Peppercorn; Blase Polite; Derek Raghavan; Gregory Rossi; Leonard Saltz; Deborah Schrag; Thomas J Smith; Peter P Yu; Clifford A Hudis; Julie M Vose; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2016-05-31       Impact factor: 44.544

Review 7.  The evidence framework for precision cancer medicine.

Authors:  Jeffrey A Moscow; Tito Fojo; Richard L Schilsky
Journal:  Nat Rev Clin Oncol       Date:  2017-12-19       Impact factor: 66.675

Review 8.  Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.

Authors:  Kathryn C Arbour; Gregory J Riely
Journal:  JAMA       Date:  2019-08-27       Impact factor: 56.272

9.  Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis.

Authors:  Scott Ramsey; David Blough; Anne Kirchhoff; Karma Kreizenbeck; Catherine Fedorenko; Kyle Snell; Polly Newcomb; William Hollingworth; Karen Overstreet
Journal:  Health Aff (Millwood)       Date:  2013-05-15       Impact factor: 6.301

10.  Financial Hardship Associated With Cancer in the United States: Findings From a Population-Based Sample of Adult Cancer Survivors.

Authors:  K Robin Yabroff; Emily C Dowling; Gery P Guy; Matthew P Banegas; Amy Davidoff; Xuesong Han; Katherine S Virgo; Timothy S McNeel; Neetu Chawla; Danielle Blanch-Hartigan; Erin E Kent; Chunyu Li; Juan L Rodriguez; Janet S de Moor; Zhiyuan Zheng; Ahmedin Jemal; Donatus U Ekwueme
Journal:  J Clin Oncol       Date:  2015-12-07       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.